KU-0060648 NEW
| Price | $54 | $106 | $172 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-09 |
Product Details
| Product Name: KU-0060648 | CAS No.: 881375-00-4 |
| Purity: 98.75% | Supply Ability: 10g |
| Release date: 2025/11/09 |
Product Introduction
Bioactivity
| Name | KU-0060648 |
| Description | KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 values of 8.6 nM, 4 nM, 0.5 nM, and 0.1 nM respectively, and demonstrates less inhibition of PI3Kγ with an IC50 of 0.59 μM. |
| Cell Research | SRB assay(Only for Reference) |
| In vitro | KU-0060648 exhibits differential effects on growth inhibition, but is not profoundly cytotoxic in a panel of human cancer cell lines. It inhibits DNA-PK and PI-3K with greater potency in MCF7 than SW620 cell using cell-based assays. Five-day exposure to 1 mM KU-0060648 inhibits cell proliferation by more than 95% in MCF7 cells but only by 55% in SW620 cells. In clonogenic survival assays, KU-0060648 increases the cytotoxicity of etoposide and doxorubicin across the panel of DNA-PKcs-proficient cells, but not in DNA-PKcs-deficient cells, confirming that enhanced cytotoxicity of the topoisomerase II poisons etoposide and doxorubicin is due to DNA-PK inhibition. [1] |
| In vivo | KU-0060648 enhances the anti-tumour activity of etoposide in both MCF7 and SW620 xenograft models, and has single-agent activity in the MCF7 xenograft model. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | PI3Kδ | PI3Kγ | PI3Kβ | PI3Kα | PI3K | Phosphoinositide 3-kinase | mTOR | Mammalian target of Rapamycin | KU-0060648 | KU 0060648 | Inhibitor | inhibit | DNA-PK | DNAPK | DNA-dependent protein kinase |
| Inhibitors Related | L-Leucine | Myricetin | Erucic acid | Sapanisertib | (2S,3R,4S)-4-Hydroxyisoleucine | 3-Methyladenine | Isoprenaline hydrochloride | Quercetin | Inavolisib | Quercetin Dihydrate | Apilimod | Rapamycin |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | Anti-Lung Cancer Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Antioxidant Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Oxidation-Reduction Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $900.00/1KG |
VIP8Y
|
.GZ HONESTCHEM CO.,LTD
|
2024-03-23 | |
| $2500.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $0.00/1g |
Wuhan Nutra Biotechnology Co.,Ltd
|
2021-05-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY